CYP19A1 and breast neoplasm: It has been shown that ER+ breast tumors of menopausal women undergoing neoadjuvant therapy with an aromatase inhibitor show an increased expression of PDGFR-β, which suggests that the PDGF pathway may be upregulated in hormone-resistant luminal tumors, making it a potential target for resistance reversal [26].